CN118451078A - 经修饰的蛋白质和蛋白质降解剂 - Google Patents
经修饰的蛋白质和蛋白质降解剂 Download PDFInfo
- Publication number
- CN118451078A CN118451078A CN202280082680.9A CN202280082680A CN118451078A CN 118451078 A CN118451078 A CN 118451078A CN 202280082680 A CN202280082680 A CN 202280082680A CN 118451078 A CN118451078 A CN 118451078A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- alkyl
- heterocyclyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2021/123848 | 2021-10-14 | ||
| CN2021123848 | 2021-10-14 | ||
| CNPCT/CN2021/133363 | 2021-11-26 | ||
| CN2021133363 | 2021-11-26 | ||
| PCT/CN2022/125080 WO2023061440A1 (en) | 2021-10-14 | 2022-10-13 | Modified proteins and protein degraders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118451078A true CN118451078A (zh) | 2024-08-06 |
Family
ID=85987275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280082680.9A Pending CN118451078A (zh) | 2021-10-14 | 2022-10-13 | 经修饰的蛋白质和蛋白质降解剂 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250235543A1 (https=) |
| EP (1) | EP4416145A1 (https=) |
| JP (1) | JP2024537394A (https=) |
| CN (1) | CN118451078A (https=) |
| AU (1) | AU2022362494A1 (https=) |
| CA (1) | CA3234615A1 (https=) |
| IL (1) | IL312013A (https=) |
| MX (1) | MX2024004525A (https=) |
| WO (1) | WO2023061440A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US20260092062A1 (en) * | 2022-09-26 | 2026-04-02 | Rectify Pharmaceuticals, Inc. | Pyridine carboxamide compounds and their use in treating medical conditions |
| CN121005703A (zh) * | 2024-05-24 | 2025-11-25 | 中国科学院广州生物医药与健康研究院 | 一种酰胺吲嗪类化合物及其制备方法和应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3445765A4 (en) * | 2016-04-22 | 2019-09-18 | Dana Farber Cancer Institute, Inc. | DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE |
| EP3807272A1 (en) * | 2018-06-13 | 2021-04-21 | Amphista Therapeutics Ltd | Bifunctional molecules for targeting rpn11 |
| US20220002291A1 (en) * | 2018-11-02 | 2022-01-06 | The Wistar Institute Of Anatomy And Biology | Proteolysis-targeting chimeras |
| WO2020173440A1 (en) * | 2019-02-27 | 2020-09-03 | Cullgen (Shanghai), Inc. | Cyclic-amp response element binding protein (cbp) and/or adenoviral e1a binding protein of 300 kda (p300) degradation compounds and methods of use |
| WO2020206608A1 (en) * | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
| WO2020219650A1 (en) * | 2019-04-23 | 2020-10-29 | Dana-Farber Cancer Institute, Inc. | Degraders of cyclin-dependent kinase 12 (cdk12) and uses thereof |
| CN112409376A (zh) * | 2019-08-20 | 2021-02-26 | 华东师范大学 | 一种基于dcaf15的蛋白降解靶向嵌合体及其制备方法和应用 |
| CN120623106A (zh) * | 2019-09-30 | 2025-09-12 | 协和麒麟株式会社 | Bet降解剂 |
| WO2021239117A1 (en) * | 2020-05-28 | 2021-12-02 | Cullgen (Shanghai) , Inc. | Modified proteins and protein degraders |
-
2022
- 2022-10-13 IL IL312013A patent/IL312013A/en unknown
- 2022-10-13 WO PCT/CN2022/125080 patent/WO2023061440A1/en not_active Ceased
- 2022-10-13 CN CN202280082680.9A patent/CN118451078A/zh active Pending
- 2022-10-13 JP JP2024522487A patent/JP2024537394A/ja active Pending
- 2022-10-13 US US18/700,898 patent/US20250235543A1/en active Pending
- 2022-10-13 MX MX2024004525A patent/MX2024004525A/es unknown
- 2022-10-13 CA CA3234615A patent/CA3234615A1/en active Pending
- 2022-10-13 AU AU2022362494A patent/AU2022362494A1/en active Pending
- 2022-10-13 EP EP22880376.3A patent/EP4416145A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024537394A (ja) | 2024-10-10 |
| US20250235543A1 (en) | 2025-07-24 |
| EP4416145A1 (en) | 2024-08-21 |
| IL312013A (en) | 2024-06-01 |
| AU2022362494A1 (en) | 2024-05-23 |
| WO2023061440A1 (en) | 2023-04-20 |
| MX2024004525A (es) | 2024-05-24 |
| CA3234615A1 (en) | 2023-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107849034B (zh) | Egfr抑制剂及其使用方法 | |
| CN118451078A (zh) | 经修饰的蛋白质和蛋白质降解剂 | |
| US9670221B2 (en) | Furopyridines as bromodomain inhibitors | |
| ES2363269T3 (es) | Amidas sustituidas, procedimiento de preparación y procedimiento de utlización de las mismas. | |
| US9834560B2 (en) | Compounds | |
| WO2020259679A1 (zh) | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 | |
| PT1477186E (pt) | Antipruriginosos | |
| AU2021269397B2 (en) | Compounds and compositions for the treatment of cancer | |
| TW202446369A (zh) | 葡萄糖依賴性促胰島素多肽受體拮抗劑及其用途 | |
| AU2006283592A1 (en) | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators | |
| RS50476B (sr) | Derivati pirazolo (4,3-d) pirimidina | |
| EP2890695A2 (en) | Kinase inhibitors | |
| JP4336738B2 (ja) | シトクロムｐ４５０３ａ４（ｃｙｐ３ａ４）の阻害剤としてのピリジンアミノスルホニル置換ベンズアミド | |
| JP2012519678A (ja) | キナーゼ阻害剤として使用されるピロロピリミジン | |
| EP2925742A1 (en) | Kinase inhibitors | |
| RU2722383C2 (ru) | Производные хромена в качестве ингибиторов фосфоинозитид-3-киназ | |
| JP6130828B2 (ja) | キナゾリンジオン誘導体 | |
| TW201022283A (en) | Fused imidazole carboxamides as TRPV3 modulators | |
| SG11202108648TA (en) | 7h-pyrrolo[2,3-d]pyrimidine-4-amine derivative | |
| JP4721452B2 (ja) | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 | |
| JP2008501618A6 (ja) | Ｐｄｅ７阻害作用を有するピリジニルピラゾロピリミジノン誘導体 | |
| CN107743489A (zh) | 用于治疗免疫疾病、炎性疾病或者癌症的7‑(吗啉‑4‑基)吡唑并[1,5‑a]嘧啶衍生物 | |
| US10696639B2 (en) | Heterocyclic compounds as HIV protease inhibitors | |
| HK40108482A (en) | Compounds and compositions for the treatment of cancer | |
| NZ795496A (en) | Aminothiazole compounds as c-Kit inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |